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Abstract
OBJECTIVES/INTRODUCTION—The incidence of chronic lung disease (CLD) varies among 
groups defined by their early pattern of respiratory disease. Although CLD is common among 
infants with continuous exposure to increased ambient oxygen throughout the first two postnatal 
weeks the antecedents of CLD among preterm infants without this exposure are not well 
understood.
PATIENTS AND METHODS—We examined data collected prospectively on the 1204 (out of 
1506) infants born in 2002 to 2004 at 23 to 27 completed weeks of gestation who survived to 36 
weeks post-menstrual age (PMA). Based on their initial respiratory presentation and need for 
supplemental oxygen during the first two weeks, infants were classified as having early and 
persistent pulmonary dysfunction (EPPD), early recovery of pulmonary function followed by 
deterioration (PD), or consistently good pulmonary function characterized by low FiO2 (Low 
FiO2).
RESULTS—CLD was diagnosed in 69% of infants with EPPD, in 52% with PD, and 17% in the 
Low FiO2 group. Risk factors for CLD varied among these groups. Birth weight z-score < -1 
Address for Correspondence: ML, Division of Neonatal-Perinatal Medicine, UNC Hospital, CB#7596, Chapel Hill, NC 27599-7596, 
matt_laughon@med.unc.edu. 
Financial Disclosure: The authors have no financial issues to disclose.
Competing Interests: The authors have no competing interests to disclose.
HHS Public Access
Author manuscript
Arch Dis Child Fetal Neonatal Ed. Author manuscript; available in PMC 2016 February 02.
Published in final edited form as:













conveyed information about CLD risk in all three groups and was the major risk factor for infants 
in the Low FiO2 group (Odds Ratio [OR] 27; 95% confidence interval [CI] 7–95). Mechanical 
ventilation at 7 days was associated with increased risk in the pulmonary deterioration group (OR 
4.2, 95% CI 2.5–6.9) and the early and persistent pulmonary dysfunction group (OR 2.7, 95% CI 
1.5–4.7), but not the Low FiO2 group (OR 1.5, 95% CI 0.5–3.9).
CONCLUSION—Both the likelihood of a very preterm infant developing CLD and the profile of 
risk factors linked with CLD are related to the infant’s pattern of respiratory disease during the 
first two postnatal weeks. Among infants with little exposure to oxygen during this period, fetal 
growth restriction, not mechanical ventilation, is the factor with the strongest association with 
CLD.
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OBJECTIVES/INTRODUCTION
Early pulmonary dysfunction in extremely low gestational age newborns (ELGANs) can be 
characterized by three distinct patterns, based on the fraction of inspired oxygen they require 
in the first two postnatal weeks.1 A minority of ELGANs have relatively normal pulmonary 
function throughout the first two postnatal weeks. Another group has pulmonary 
deterioration (PD), characterized by resolving lung disease during the first postnatal week, 
and followed in the second week by a requirement for increased supplemental oxygen and, 
in some cases, mechanical ventilation. A third group has early and persistent pulmonary 
dysfunction (EPPD) requiring mechanical ventilation and high concentrations of 
supplemental oxygen throughout this time period.
The incidence of chronic lung disease (CLD), also known as bronchopulmonary dysplasia, 
varies among groups defined by their early respiratory function. Among infants with EPPD, 
approximately two-thirds develop CLD, and the oxygen and ventilation exposures in this 
group most resemble historical antecedents of BPD.1 Infants with PD are at moderate risk of 
CLD and have less exposure to oxygen and ventilation than EPPD infants. Although almost 
one-fifth of infants with relatively normal lung function throughout the first two postnatal 
weeks develop CLD, they have virtually no exposure to supplemental oxygen and 
ventilation during that period. These observations suggest that several pathophysiologic 
pathways play a role in the development of CLD. Understanding the relative contribution of 
CLD antecedents within these groups might provide clues to the mechanisms of injury that 
lead to CLD.
The objective of this study was to identify clinical and demographic antecedents and 
modifiers of CLD risk in three groups of infants defined by their pattern of early postnatal 
respiratory function.
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The infants included in this analysis are a subset of infants enrolled in a multi-center 
epidemiologic study to identify characteristics and exposures that increase the risk of 
structural and functional neurologic disorders in ELGANs (the ELGAN Study).12 From 
March 2002 to August 2004, women delivering before the 28th week of gestation at one of 
14 participating institutions were asked to enroll in the study. Individual institutional review 
boards at each of the institutions approved the enrollment and consent processes (see 
Acknowledgements for the list of institutions that approved the study). Of 1506 infants 
enrolled, 1204 had both the information necessary to make an early respiratory status 
assignment and survived to 36 weeks post-menstrual age (PMA) when a CLD diagnosis was 
made.
Patterns of Early Respiratory Function and Chronic Lung Disease
ELGANs were classified into three mutually exclusive groups: those with relatively normal 
pulmonary function (Low FiO2 group: FiO2 consistently < 0.23 on all days between 3 and 7 
postnatal days and receiving FiO2 ≤ 0.25 on Day 14), those with pulmonary deterioration 
during the second week of life after a period of normal lung function (PD group: FiO2 < 
0.23 on any days between 3 and 7 days and receiving FiO2 > 0.25 on day 14), and those with 
early and persistent pulmonary dysfunction (EPPD group: FiO2 consistently ≥ 0.23 on all 
days between 3 and 7 postnatal days and receiving FiO2 > 0.25 on Day 14).1 There were no 
patients with an FiO2 > 0.23 on any day between 3 and 7 postnatal days and receiving < 
0.25 on Day 14, so this group was not included. The diagnosis of CLD was based on 
whether or not the child was receiving supplemental oxygenation at 36 weeks PMA.
Demographic, Pregnancy and Neonatal Variables
Pregnancy characteristics and data describing newborns at the time of delivery included 
maternal race, receipt of antenatal steroids, chorioamnionitis, pregnancy complications, 
multi-fetal pregnancy, gender, gestational age, and birth weight. The birth weight Z-score is 
the number of standard deviations the infant’s birth weight is above or below the median 
weight of infants at the same gestational age in a standard data set.3
The SNAP-IITM (Score for Neonatal Acute Physiology-II)4 was calculated from measures 
taken during the first 12 hours of life. Mode of ventilation was defined as the highest level 
of support on each day and ranged from no support, supplemental oxygen by hood or nasal 
cannula, nasal continuous positive airway pressure, and conventional mechanical ventilation 
to high frequency ventilation and was recorded on days 0–7, 14, 21, and 28, and at 36 weeks 
PMA. We also recorded the number of days each infant received supplemental oxygen, 
CPAP, and conventional mechanical ventilation (including high frequency ventilation). 
Diagnoses of pneumothorax, pulmonary interstitial emphysema, and pulmonary hemorrhage 
were those made by the clinicians caring for the infant.
Confirmed early bacteremia was defined as recovery of an organism from blood drawn 
during the first postnatal week, and confirmed late bacteremia as recovery of an organism 
Laughon et al. Page 3













from blood drawn during the second, third or fourth week. Confirmed tracheal colonization 
required the recovery of a pathogen from tracheal aspirate.
The diagnosis of PDA was made by clinicians using their own operational definitions, which 
might or might not have included echocardiographic findings. We did not record the day of 
diagnosis. We recorded whether the PDA was ligated and whether indomethacin was offered 
as medical therapy. If a child had surgical ligation of the PDA, the infant was assigned to the 
surgical therapy group only, even if the infant first received medical therapy. Infants 
classified as having received medical therapy received indomethacin and did not have the 
PDA ligated.
The presence of chorioamnionitis and funisitis was determined by an ELGAN study 
pathologist at each institution who first engaged in training procedures to minimize inter-
observer variability, was masked to maternal history, and used pre-defined operational 
definitions; 1126 placentas were examined.56
Medications were recorded if given on any day during the first week through fourth weeks, 
and included surfactant, analgesics (i.e., morphine, fentanyl, or methadone), sedatives (i.e., 
lorazepam, midazolam, or chloral hydrate), vitamin A, and steroids (i.e., hydrocortisone and 
dexamethasone). Indications were not recorded.
Data Analysis
We evaluated whether groups of antecedents of CLD differed among the three early 
respiratory pattern groups. First we calculated risks of CLD among infants classified by their 
early respiratory pattern and the presence or absence of other characteristics and exposures. 
The characteristics that most clearly distinguished infants at highest risk of CLD from their 
peers were then included in logistic regression models to assess the strength of association 
of each characteristic/exposure to the risk of CLD within each early respiratory pattern 
group, while adjusting for other factors included in the regression. Gestational age 
categories (23–24, 25–26, 27 weeks) and birth weight Z-score groups (<-2, ≥ -2 but <-1, ≥ 
-1) 78 were included in every multivariable model.
Because postnatal phenomena, such as the need for ventilatory assistance, can be influenced 
by antepartum phenomena, we created logistic regression models in which risk factors are 
ordered in a temporal pattern, so that the earliest occurring predictors/covariates of an 
outcome (e.g., CLD) are entered first and are not displaced by later occurring covariates 
work.9–14 For these time-oriented risk models (TORMs), we categorize sets of antecedents/
covariates by the time they occur or are identified. We grouped prenatal and birth 
characteristics and exposures into the antenatal epoch, all exposures and characteristics 
during the first week into the early neonatal epoch, and exposures and characteristics 
occurring or reported between weeks 2–4 into the late neonatal epoch. We included in the 
antenatal epoch a hospital stratum (group) term to account for the possibility that infants 
born at a particular hospital are more like each other than like infants born at other 
hospitals.15 Because the risk of CLD among infants born with a sibling did not differ from 
that of singletons, we did not adjust for number of fetuses.
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We used a step down procedure within each epoch, seeking a parsimonious solution without 
interaction terms. After the antenatal epoch variables were identified, the early neonatal 
variables were added. We then dropped non-significant neonatal variables but did not permit 
displacement of antenatal variables. Finally, the late neonatal epoch variables were added to 
the reduced antenatal/early neonatal set and non-significant late neonatal variables dropped. 
The contributions of relevant variables in the final model are presented as odds ratios with 
95% confidence intervals. We created three TORMs of CLD, one for each pattern of early 
respiratory function.
RESULTS
Among 1506 infants enrolled in the ELGAN Study, 1204 survived to 36 weeks PMA and 
constitute the cohort for this study (Figure). The early respiratory function was categorized 
as EPPD in 42% (n=508) of the infants, as PD in 38% (n=456), and as Low FiO2 in 20% 
(n=240). The incidence of CLD varied among groups defined by these respiratory patterns 
during the first two postnatal weeks. CLD was diagnosed in 69% of infants in the EPPD 
group, 52% in the PD group, and 17% in the Low FiO2 group.
Univariate Analyses
Antenatal factors [Table 1]—Lower gestational age and lower birth weight were 
associated with an increased risk of CLD in all respiratory-pattern groups. Lower birth 
weight z-scores were associated with an increased risk of CLD in all groups, particularly in 
the Low FiO2 group. In this group, 38% of infants with a birth weight Z-score between -2 
and -1 and 70% of infants with a birth weight Z-score of < -2 developed CLD, compared to 
13% among appropriate for gestational age birth weight infants. Among infants in the Low 
FiO2 group, those delivered for maternal indications (preeclampsia) were at an increased 
risk of CLD (40%, compared to 10–19% among other indications for delivery). In the PD 
group, male infants were more likely to develop CLD (56% vs. 47% among female infants). 
Aside from gestational age, birth weight and birth weight z-score, no antenatal characteristic 
or exposure among infants in the EPPD group conveyed information about the risk of CLD.
Early neonatal factors [Table 2]—A SNAP-II™ greater than 30 and receipt of 
mechanical ventilation on postnatal day 7 were associated with an increased risk of CLD in 
all groups. In the Low FiO2 group, receipt of dexamethasone, vitamin A, analgesics, and 
sedation were associated with an increased risk of CLD. In the PD group, receipt of 
surfactant, hydrocortisone, dexamethasone, and analgesics, as well as confirmed bacteremia 
and tracheal infection, were associated with an increased risk of CLD. In the EPPD group, 
receipt of surfactant was associated with an increased risk of CLD and receipt of 
dexamethasone, sedation, and vitamin A were associated with a decreased risk of CLD.
Late neonatal factors [Table 3]—In all groups, infants who received dexamethasone, 
analgesics, or sedation, as well as those who were ventilated on day 14 or 21, had confirmed 
tracheal infection, developed pneumothorax or isolated intestinal perforation, were at 
increased risk of CLD. In the Low FiO2 group, receipt of hydrocortisone and vitamin A, or 
required surgery for necrotizing enterocolitis were associated with an increased risk of CLD. 
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Infants in the PD group were at increased risk of CLD if they received hydrocortisone, had 
confirmed bacteremia, or required surgery for necrotizing enterocolitis. In the EPPD group, 
confirmed bacteremia and PDA were associated with an increased risk, and receipt of 
vitamin A was associated with a decreased risk of CLD.
Placenta histology and microbiology [Table 4]—Thrombosis of fetal stem vessels, 
infarcts, and increased syncytial knots were associated with an increased risk of CLD, and 
this was most pronounced in the Low FiO2 group. In all groups, no organism or group of 
organisms recovered from the placenta conveyed information about CLD risk (data not 
shown).
Time Oriented Risk Models [Table 5]
Low FiO2 group—In the Low FiO2 group, birth weight z-score < -1 was associated with 
an increased risk of CLD. In the early neonatal epoch, only SNAP-IITM >30 was associated 
with an increased risk of CLD, while receipt of surfactant was associated with a reduced 
risk. In the late neonatal epoch, receipt of analgesics was associated with an increased risk of 
CLD. The presence of pulmonary interstitial emphysema was also associated with increased 
risk; however, this diagnosis was assigned to only six infants.
PD group—Infants in the PD group were at increased risk of CLD if their gestational age 
was < 27 weeks, their birth weight Z-score was < -1, and they were male. In the early 
neonatal epoch, SNAP-IITM >30, definite bacteremia, and mechanical ventilation on day 7 
were associated with an increased risk of CLD, while a diagnosis of pneumothorax in the 
late neonatal epoch was associated with an increased risk of CLD.
EPPD group—Among infants in the EPPD group, those whose gestational age was 23–24 
weeks, had a birth weight Z-score of < -1 were at increased risk of CLD. Delivery for 
preeclampsia or a fetal indication approached nominal statistical significance. Only 
mechanical ventilation on day 7 entered in the early neonatal epoch, while two late neonatal 
variables, pulmonary interstitial emphysema and receipt of hydrocortisone, provided 
additional information about an increased risk of CLD.
DISCUSSION
In this study, we evaluated CLD risk factors in three groups of infants characterized by their 
pulmonary function during the first two weeks after birth. These groups differed in their 
likelihood of developing CLD. Differences in early exposure to oxygen might not only have 
defined these three groups, but also influenced CLD risk. However, we hypothesized that 
each group had its own risk profile for CLD that included factors not directly related to 
pulmonary function or therapies. We were particularly interested in antecedents of CLD 
among infants with little exposure to increased concentrations of oxygen during early life 
(the Low FiO2 group). Although multiple factors were significant in univariate analysis 
(e.g., vitamin A), once adjustments were made in multivariate analysis, many of these were 
no longer significant.
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In a previous report, we demonstrated that fetal growth restriction was the antenatal factor 
that best predicted CLD.16 In the current study, fetal growth restriction was associated with 
increased CLD risk in all groups defined by early pulmonary function, even after adjustment 
for early and late postnatal neonatal exposures and other morbidities. The observation that 
this effect was most pronounced in the Low FiO2 group suggests that processes that limit 
fetal growth might predispose to abnormal lung growth before and after birth, ultimately 
resulting in pulmonary dysfunction. This cascade of events appears to occur even in the 
absence of exposures likely to result in lung injury.
Severe growth restriction might contribute to CLD risk in several ways. First, factors that 
impair fetal somatic growth might also impair lung development, resulting in abnormal 
development of terminal air sacs and alveoli, or abnormal pulmonary angiogenesis.17 This 
might be similar to the changes characteristic of the "new BPD".1819
Second, an imbalance between angiogeneic and anti-angiogeneic factors might disrupt 
normal placental angiogenesis and abnormal fetal angiogenesis, including the vasculature of 
the fetal lung. Preeclampsia is the disorder most closely associated with fetal growth 
restriction and is also associated with disturbed angiogenesis.20 Our observation of an 
increased risk of CLD among those whose placenta had increased syncytial knots, a 
histologic abnormality characteristic of preeclampsia, supports this possibility.
Third, chronic fetal hypoxia, sometimes identified as a factor that impairs growth21, might 
be accompanied by impaired lung development. This possibility is supported by 
observations from animal studies. Impaired alveolar and pulmonary artery development 
occurs in neonatal mice exposed to chronic hypoxia during the first two weeks of life, a 
period of lung development that corresponds to human fetal lung development during the 
third trimester.22 Regardless of the mechanism, the interaction between factors that control 
fetal somatic growth and lung maturation is complicated.
Fetal growth restriction also was associated with CLD in the PD group and to a lesser extent 
in the EPPD group. In the PD group, characteristics associated with gestational age and male 
gender appear to have influenced CLD risk. In addition, among neonatal exposures, 
mechanical ventilation was most influential. Although gestational age and FGR were 
important in the EPPD group, mechanical ventilation at 7 days and dexamethasone treatment 
in the late neonatal period were the factors most strongly associated with CLD. The latter 
association probably reflects selective use of this therapy in infants likely to develop CLD. 
PIE was also associated with increased risk. These observations suggest that even in the 
absence of vulnerability imparted by growth restriction, infants with PD are particularly 
vulnerable to CLD due to extreme immaturity or exposures that injure the lung (e.g. high 
oxygen concentrations and mechanical ventilation).
In the Low FiO2 group and EPPD group, exposure to analgesics and dexamethasone, 
respectively, during the late neonatal period was associated with an increased risk of CLD. 
For the Low FiO2 group, one possibility is that analgesic use itself renders an infant more 
likely to develop CLD, directly or through secondary effects. Narcotics, such as morphine, 
depress the respiratory drive and might therefore prolong the need for mechanical 
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ventilation and, thus, increase the risk of ventilator-induced lung injury. In a randomized 
controlled trial 23, infants treated with mechanical ventilation who were allocated to receive 
continuous morphine infusions were ventilated for one week longer than infants allocated to 
placebo.24 Another explanation for this observation is that exposure to analgesics or 
dexamethasone is indicative of greater illness severity or longer duration of mechanical 
ventilation. A more valid conclusion about dexamethasone is available from meta-analyses 
of randomized, placebo controlled trials,2526 which indicate that this treatment reduces the 
risk of CLD. The decision to treat an infant with an analgesic or to ventilate an infant might 
reflect the physician’s perception that the infant is sufficiently ill to require these therapies, 
rather than analgesics or ventilation contributing to CLD risk. Alternatively, many infants 
treated with mechanical ventilation receive analgesics, for sedation. This is an example of 
confounding by indication, a problem common to many epidemiologic studies incorporating 
clinical decisions as variables, outcomes or exposures.2728 For example, later-occurring 
conditions or events, such as necrotizing enterocolitis or PDA ligation, might both require 
treatment with narcotic analgesics and increase the risk of CLD through pathogenic 
mechanisms not involving the medication.
Intra-amniotic inflammation has been implicated in the development of so-called atypical 
CLD (i.e. CLD not preceded by respiratory distress syndrome).29 All infants in our Low 
FiO2 group and many infants in our PD group would have been classified as having atypical 
CLD using this definition. We found no association between CLD and either histologic 
markers of placental inflammation or microbiologic evidence of placental infection and 
CLD in groups defined by their early lung function. Our data suggest that intrauterine 
infection is unlikely to be a risk factor for CLD, regardless of the presence or absence or 
early respiratory disease. Chorioamnionitis has been inconsistently reported as affecting 
respiratory outcomes (respiratory distress syndrome and CLD)3031, most likely because the 
diagnosis of chorioamnionitis is challenging and does not provide information about the 
organism, duration, or extent of fetal involvement. One possibility that we did not find an 
association is that respiratory care practices in ELGAN centers might have attenuated the 
putative pathway to CLD that involves intrauterine inflammation followed by postnatal 
ventilator-induced lung injury.31
We did not observe a relationship between severe NEC and CLD risk, as has been reported 
previously.3233 One explanation for the difference in these findings is that our sample size 
permitted adjustment for a large number of confounders and antecedents. Another is that 
antenatal phenomena contributed to both CLD and NEC, but by our use of time oriented 
regression modeling we reduced the probability of perceiving an epiphenomenon (such as 
NEC) as a risk factor.
Conclusion
The risk of CLD varies among infant groups defined by their pulmonary function during the 
first two postnatal weeks. Among infants with little exposure to oxygen during this period, 
FGR is the factor most strongly associated with CLD. Among infants with PD or EPPD, 
other factors, such as gestational age, male gender, and mechanical ventilation also convey 
nearly as much or more information about CLD risk. Therefore, CLD among infants with 
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little exposure to oxygen early in life might result almost exclusively from fetal phenomena 
related to lung growth. These observations have the potential to inform future investigations 
of the biological mechanisms underlying the association between patterns of early 
pulmonary function and the development of CLD.
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"What is already known on this topic" –Pulmonary dysfunction in the first two postnatal 
weeks in preterm infants can be characterized into three groups by the fraction of inspired 
oxygen they require. The risk of chronic lung disease varies among infant groups defined 
by their pulmonary function during the first two postnatal weeks.
"What this study adds" –Among infants with little exposure to oxygen during this period, 
fetal growth restriction is the factor most strongly associated with chronic lung disease. 
Among infants with pulmonary deterioration or early and persistent pulmonary 
dysfunction, other factors, such as gestational age, male gender, and mechanical 
ventilation convey nearly as much or more information about chronic lung disease risk as 
fetal growth restriction.
Laughon et al. Page 12














Derivation of cohort. EPPD=early and persistent pulmonary dysfunction (an FiO2 
consistently ≥ 0.23 on all days between 3 and 7 postnatal days and receiving FiO2 > 0.25 on 
Day 14); PD=Pulmonary Deterioration (an FiO2 < 0.23 on any days between 3 and 7 days 
and receiving FiO2 > 0.25 on day 14); Low FiO2=consistently low FiO2 (an FiO2 
consistently < 0.23 on all days between 3 and 7 postnatal days and receiving FiO2 ≤ 0.25 on 
Day 14). CLD=chronic lung disease among survivors.
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Table 5
Odds ratios and 95% confidence intervals obtained with time-oriented risk models of chronic lung disease for 
three patterns of respiratory disease (Low FiO2, Pulmonary Deterioration [PD], or Early and Persistent 
Pulmonary Dysfunction [EPPD]) during the first four postnatal weeks.
1. Antenatal Low FiO2 PD EPPD
GA 23–24 wks 3.2 (2.0, 8.8) 2.5 (1.5, 4.3)
GA 25–26 wks 1.9 (1.1, 3.1)
BW Z-score < −1 26 (7.0, 95) 4.4 (2.3, 8.2) 2.0 (1.1, 3.9)
Male 1.9 (1.2, 3.1)
Cesarean delivery 0.5 (0.2, 1.2)
Indication is PE or FI 1.9 (0.98, 3.8)
2. Early neonatal (week 1)
SNAP-IITM 30+ 3.3 (1.02, 11) 2.0 (1.1, 3.9)
Definite bacteremia 2.6 (1.01, 6.9)
Surfactant 0.2 (0.1, 0.7)
Mechanical ventilation on day 7 1.5 (0.5, 3.9) 4.2 (2.5, 6.9) 2.7 (1.5, 4.7)
3. Late neonatal (weeks 2–4)
Dexamethasone 3.0 (1.2, 7.2)
Analgesic 3.4 (1.2, 9.5)
PTX 1.9 (1.1, 3.2)
PIE 17 (2.1, 140) 2.6 (1.5, 4.6)
Variables offered:
Antenatal epoch: gestational age 23–24 weeks, gestational age 25–26 weeks, birth weight Z-score, sex, complete course of antenatal steroids, 
multiple birth, cesarean delivery, delivery for preeclampsia or fetal indication, thrombosis of the fetal stem vessels in the placenta
Early neonatal epoch (week 1): SNAP-IITM ≥ 30, confirmed early bacteremia, confirmed tracheal infection, receipt of surfactant, hydrocortisone, 
dexamethasone, analgesic, sedation, or vitamin A, mechanical ventilation
Late neonatal epoch (weeks 2–4): confirmed bacteremia, confirmed tracheal infection, receipt of hydrocortisone, dexamethasone, analgesics, 
sedation, or vitamin A, patent ductus arteriosus, pneumothorax, pulmonary interstitial emphysema
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